Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer (PASCART)
Recruitment status was: Not yet recruiting
Patients undergoing lung resection due to pulmonary cancer can be compromised in their postoperative period due to atrial fibrillation.
A retrospective analysis performed at our institution indicates that 30 % of the population develope atrial fibrillation in the postoperative period.
Amiodarone is known to diminish the occurence of postoperative atrial fibrillation after heart surgery, why this drug is chosen as a prophylactic agent for the mentioned population.
Amiodarone is administrated twice a day for 5 days at a dose of 600 mg oral treatment after an initial loading bolus og 300 mg intravenously.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
|Official Title:||Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial|
- Free of atrial fibrillation [ Time Frame: 31082009 ] [ Designated as safety issue: Yes ]
- Cost-benefit analysis of amiodarone prophylactic [ Time Frame: 31082009 ] [ Designated as safety issue: No ]
|Study Start Date:||August 2008|
|Estimated Study Completion Date:||December 2009|
|Estimated Primary Completion Date:||August 2009 (Final data collection date for primary outcome measure)|
intravenous bolus of 300 mg oral treatment og 600 mg twice a day for five days
Please refer to this study by its ClinicalTrials.gov identifier: NCT00724581
|Aarhus University Hospital, Skejby|
|Aarhus, Denmark, DK-8200|
|Principal Investigator:||Lars R Zebis, MD, Ph.D.||Aarhus University Hospital Skejby|